TNSN01169A1 - Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase. - Google Patents

Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.

Info

Publication number
TNSN01169A1
TNSN01169A1 TNTNSN01169A TNSN01169A TNSN01169A1 TN SN01169 A1 TNSN01169 A1 TN SN01169A1 TN TNSN01169 A TNTNSN01169 A TN TNSN01169A TN SN01169 A TNSN01169 A TN SN01169A TN SN01169 A1 TNSN01169 A1 TN SN01169A1
Authority
TN
Tunisia
Prior art keywords
compositions
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
precursors
Prior art date
Application number
TNTNSN01169A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01169A1 publication Critical patent/TNSN01169A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS COMPRENANT UN AGONISTE DE GABA, OU UN DE SES PRECURSEURS MEDICAMENTEUX OU BIEN UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CET AGONISTE DE GABA OU DE CE PRECURSEUR MEDICAMENTEUX ET UN SDI OU UN DE SES PRECURSEURS MEDICAMENTEUX, OU BIEN UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CE SDI OU DE CES PRECURSEURS MEDICAMENTEUX. ELLE CONCERNE EGALEMENT DES KITS CONTENANT CES ASSOCIATIONS. APPLICATION : UTILISATION DES COMPOSITIONS POUR LE TRAITEMENT DES COMPLICATIONS DU DIABETE CHEZ DES MAMMIFERES, Y COMPRIS L'HOMME.
TNTNSN01169A 2000-11-30 2001-11-29 Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase. TNSN01169A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
TNSN01169A1 true TNSN01169A1 (fr) 2005-11-10

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01169A TNSN01169A1 (fr) 2000-11-30 2001-11-29 Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.

Country Status (38)

Country Link
US (1) US6544998B2 (fr)
EP (1) EP1337271B1 (fr)
JP (1) JP2004514699A (fr)
KR (1) KR20030059290A (fr)
CN (1) CN1477975A (fr)
AP (1) AP2001002360A0 (fr)
AR (1) AR031431A1 (fr)
AT (1) ATE281181T1 (fr)
AU (1) AU2002215159A1 (fr)
BG (1) BG107774A (fr)
BR (1) BR0115783A (fr)
CA (1) CA2430298A1 (fr)
CR (1) CR6964A (fr)
CZ (1) CZ20031399A3 (fr)
DE (1) DE60106968T2 (fr)
DO (1) DOP2001000289A (fr)
EA (1) EA200300432A1 (fr)
EC (1) ECSP034624A (fr)
EE (1) EE200300248A (fr)
ES (1) ES2230378T3 (fr)
HR (1) HRP20030420A2 (fr)
HU (1) HUP0302160A3 (fr)
IL (1) IL155704A0 (fr)
IS (1) IS6786A (fr)
MA (1) MA26964A1 (fr)
MX (1) MXPA03004870A (fr)
NO (1) NO20032441L (fr)
OA (1) OA12534A (fr)
PA (1) PA8534101A1 (fr)
PE (1) PE20020597A1 (fr)
PL (1) PL365927A1 (fr)
PT (1) PT1337271E (fr)
SK (1) SK6192003A3 (fr)
SV (1) SV2003000751A (fr)
TN (1) TNSN01169A1 (fr)
UY (1) UY27042A1 (fr)
WO (1) WO2002043762A2 (fr)
ZA (1) ZA200303381B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
SK286227B6 (sk) 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
WO2005097079A2 (fr) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Formes galeniques pharmaceutiques a liberation immediate et/ou controlee renfermant un agoniste du recepteur gabab
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
TWI385152B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (I)
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
MX2009011600A (es) 2007-04-27 2010-11-26 Purdue Pharma Lp Antagonistas de trpvi y usos de los mismos.
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
EP2621282B1 (fr) * 2010-09-28 2020-04-15 The Regents of The University of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
SI2723732T1 (sl) 2011-06-22 2017-05-31 Purdue Pharma Lp One Stamford Forum Antagonisti trpv1, vključno z dihidroksi substituentom, in njihova uporaba
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955918A1 (fr) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Procédés pour traiter les troubles neurocognitifs, la douleur chronique, et pour réduire l'inflammation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
CS234018B2 (en) 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
EP0662962A1 (fr) * 1992-09-28 1995-07-19 Pfizer Inc. Pyrimidines substituees pour le controle des complications diabetiques
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
NZ514144A (en) * 1999-04-01 2001-09-28 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
DK1041068T3 (da) * 1999-04-01 2004-05-10 Pfizer Prod Inc Compounds for treating and preventing diabetic complications

Also Published As

Publication number Publication date
ECSP034624A (es) 2003-07-25
NO20032441L (no) 2003-07-03
PT1337271E (pt) 2005-01-31
WO2002043762A3 (fr) 2003-03-13
BG107774A (en) 2004-01-30
AR031431A1 (es) 2003-09-24
ATE281181T1 (de) 2004-11-15
BR0115783A (pt) 2003-09-16
UY27042A1 (es) 2002-07-31
HUP0302160A3 (en) 2005-05-30
CA2430298A1 (fr) 2002-06-06
EE200300248A (et) 2003-10-15
NO20032441D0 (no) 2003-05-28
EP1337271A2 (fr) 2003-08-27
US20020091128A1 (en) 2002-07-11
PL365927A1 (en) 2005-01-10
IL155704A0 (en) 2003-11-23
PE20020597A1 (es) 2002-07-08
KR20030059290A (ko) 2003-07-07
US6544998B2 (en) 2003-04-08
DE60106968T2 (de) 2005-11-03
OA12534A (en) 2006-06-05
ES2230378T3 (es) 2005-05-01
PA8534101A1 (es) 2002-10-31
HUP0302160A2 (hu) 2003-11-28
ZA200303381B (en) 2004-04-30
MXPA03004870A (es) 2003-08-19
IS6786A (is) 2003-04-14
HRP20030420A2 (en) 2004-08-31
EP1337271B1 (fr) 2004-11-03
CN1477975A (zh) 2004-02-25
DOP2001000289A (es) 2003-02-15
SV2003000751A (es) 2003-01-13
CZ20031399A3 (cs) 2004-04-14
EA200300432A1 (ru) 2003-10-30
SK6192003A3 (en) 2004-07-07
MA26964A1 (fr) 2004-12-20
WO2002043762A2 (fr) 2002-06-06
CR6964A (es) 2004-02-02
DE60106968D1 (de) 2004-12-09
JP2004514699A (ja) 2004-05-20
AP2001002360A0 (en) 2001-12-31
AU2002215159A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
TNSN01169A1 (fr) Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.
TNSN01170A1 (fr) Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
HUP0004348A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
TNSN01119A1 (fr) Compositions contenant des inhibiteurs de la proteine de transfert d'ester de cholesteryle
TNSN02037A1 (fr) Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2329636A1 (fr) Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson
FI971207A (fi) Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen
ATE228849T1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
PT867178E (pt) Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
TNSN99214A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
BG105302A (en) Means for improving cognition